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February 2, 2010:499–506hat different types of stress may explain different results is certainly
nteresting, and deserves further in-depth studies on larger populations.
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ierre Soulié, a
Pre-Echocardiographic” Pioneer
f Hypertrophic Cardiomyopathy
aron et al. (1) recently issued an in-depth review of evolving
oncepts for hypertrophic cardiomyopathy. These prestigious in-
estigators report the concordant or controversial issues discussed
ver 50 years. They finally present an understanding of the disease
onsistent with the early descriptions.
I understand that the report is clearly dedicated to the evolving
pinions and debates generated by the disease in the last 50 years.
also am well aware of the decisive contribution of echocardiog-
aphy for understanding its mechanism since 1969 and of the value
f genetics for the study of the transmission of the disease and its
eterogeneous clinical spectra. Nevertheless, grouping important
ontributions of researchers who deciphered its early characteristic
eatures from 1957 to about 1967 under the nonspecific “pre-chocardiographic” era, in the way historians refer to the B.C.
eriod, is at risk to overlook some pioneers.
In the late 1950s, namely from 1957 to 1959, all the cards were
ot in the same hands to diagnose hypertrophic cardiomyopathy;
n the one hand, when looking at ventricular walls, it was on
rrested heart for surgeons (2) or at necropsy for anatomists. This
nabled the discovery of asymmetrical septal hypertrophy (3), but
he dynamic features lacked the ability necessary to recognize the
isease; the global hypertrophy found at surgery or necropsy was
nterpreted as residual in the outflow tract after reduction of a
alvular or subvalvular membranous stenosis or secondary to
ystemic hypertension, or of unknown origin (2,4–5). On the other
and, those studying the beating heart with their mere ears,
ngers, and stethoscopes did not “see” the underlying cardiac
tructures’ abnormalities and attributed the murmurs they heard to
heumatic aortic stenoses, which were the rule. Titles of papers
eflect their astonishment (2,4–6). In 1958, Pierre Soulié was the
rst to link asymmetrical septal hypertrophy, subvalvular pressure
radient, and the typical arterial pattern in the new concept of a
true subvalvular muscular stenosis” in a paper presented at the
rench Society of Cardiology (October 19, 1958). Detailed find-
ngs were printed later in September 1959 (6). Typical features of
he arterial pressure tracings were shown and detailed: initial rapid
pstroke followed by a lower prolonged tidal wave accounting for
he hindrance to flow due to the “nonpermanent systolic muscular
bstruction.” He emphasized its diagnostic value versus valvular
tenosis. Although Brock (2) had vaguely noted such a transitory
attern on some contractions without drawing any diagnostic
nformation (Fig. 11 in Brock [2]), confirmation of the arterial
attern came from Brachfeld and Gorlin’s later review (7).
Reading Soulié’s paper shows an obvious observational advance
ver previous references (2,4,5). Finally, Soulié’s hypothesis about
he septal subvalvular site of the murmur was later substantiated by
ntracardiac phonocardiography (8). Similar features were found on
ow velocity traces in the aorta (9) and later transcutaneously (10).
Rapidly improving invasive procedures added complementary
nformation at the end of this “pre-echocardiographic” era. The
tage was, thus, ready for echocardiographic and genetic studies to
omplement the whole spectrum of the disease.
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eriprocedural Myocardial Injury:
ot a Benign Entity
rasad et al. (1) present valuable insights into the prognostic
nfluence of spontaneous myocardial infarction (SMI) and peripro-
edural myocardial infarction (PMI) following stent insertion in
he ACUITY (Acute Catheterization and Urgent Intervention
riage Strategy) trial. They concluded that PMI is of limited
rognostic significance as it is predominantly a marker for procedural
nd baseline risk factors, and that, in contrast to SMI, it does not
ave independent prognostic significance. Given the differences in
he pathophysiology, it is unsurprising that PMI and SMI have
ifferential influence on prognosis at 1 year, but we wish to
uestion some of the investigators’ interpretation of their data, as
e feel that the significance of PMI has been understated.
Their principal conclusion about the lack of prognostic influ-
nce is based on the 1-year mortality hazard ratio for PMI being
ound to be not significant after adjustment for procedural and
aseline characteristics. In this study, both PMI (3.2% vs. 0.8%,
 0.0001) and SMI (5.0% vs. 0.8%, p  0.0001) are associated
ith higher 30-day mortality without any significant difference
etween the 2 types of myocardial infarction (p 0.27). No hazard
atio for 30-day mortality after the time-updated covariate-
djusted multivariate analysis is quoted, but the Kaplan-Meier
raphs show similar curves for SMI and PMI in the early
ost-procedural period, suggesting that both types of myocardial
nfarction predict an adverse short-term outcome. Interestingly,
tent thrombosis in patients that sustained PMI appears to have a
orse prognosis than SMI without stent thrombosis.
The relevance of periprocedural enzyme elevation has been the
opic of considerable debate, but it is increasingly clear that even
mall periprocedural troponin rises reflect new areas of myocardial
ecrosis on magnetic resonance imaging (2,3). Debate persists
bout the influence on prognosis of these small/moderate enzyme
ises, but there is little doubt about the influence of large
eriprocedural enzyme rises—even in this study, the 1-year mor-
ality for Q-wave PMI is extremely high at 27%, versus 17.3% for
-wave SMI (p  0.22).
Previous studies from patients undergoing nonemergency per-
utaneous coronary intervention, whether using creatine kinase-
yocardial band or troponin definitions of PMI, have shown that
MI is an adverse long-term prognosticator (4–6). It is notable in
his study of patients with acute coronary syndromes that a nefinition combining new elevation of 3 creatine phosphoki-
ase or creatine kinase-myocardial band and electrocardiography
riteria has been used for PMI. Troponin, a more sensitive and
pecific biomarker, is not used for the diagnosis of PMI but is used
or the diagnosis of SMI.
We agree that PMI and SMI are different entities, and
nevitably SMI would portend a worse prognosis. However, we feel
hat PMI with imaging evidence of myocardial necrosis represents
n adverse event with long-term outcome implications. The
ong-term consequences of minor periprocedural enzyme rises are
ore uncertain and need more investigation, especially with the
dvent of the new universal definition of PMI using a troponin
utoff of 3 the 99th percentile (7).
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eply
e thank Dr. Lim and colleagues for their interest in our paper
1). While agreeing with the principal finding of our study (1) that
pontaneous myocardial infarction (SMI) portends a worse prog-
osis than periprocedural myocardial infarction (PMI), Lim and
